OncoMatch/Clinical Trials/NCT05568680
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Is NCT05568680 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR for ovarian cancer.
Treatment: SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR — This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Cholangiocarcinoma
Mesothelioma
Biomarker criteria
Required: MSLN overexpression
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy — advanced disease
after at least 1 prior line of systemic therapy for advanced disease
Cannot have received: gene-engineered T cell therapy
previous gene-engineered T cell therapies
Lab requirements
Blood counts
Satisfactory organ and bone marrow function
Kidney function
Satisfactory organ and bone marrow function
Liver function
Satisfactory organ and bone marrow function
Satisfactory organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Kansas Cancer Center · Westwood, Kansas
- University of Pennsylvania · Philadelphia, Pennsylvania
- MD Anderson Cancer Center · Houston, Texas
- University of Wisconsin Carbone Cancer Center · Madison, Wisconsin
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05568680 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior gene-engineered T cell therapy disqualifies patients from enrollment.
Does this trial require MSLN?
Yes, MSLN overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages